Kantesti Expands Across Europe, Reaches 2 Million Users Globally

New Delhi [India], January 9: Kantesti, the AI-powered blood test analysis platform developed by PIYA AI, has announced a major expansion across European markets as its global user base surpasses 2 million people spanning 127 countries. The milestone underscores growing international adoption of AI-assisted diagnostic support tools designed to make complex medical data more accessible and actionable.

With operational hubs established in Cologne, Milan, and Paris, Kantesti has positioned itself at the forefront of Europe’s rapidly evolving digital health ecosystem. Its multilingual platform, supporting more than 75 languages, has enabled broad adoption across diverse healthcare systems and patient populations.

Clinical-Grade Accuracy with Global Accessibility

Kantesti’s AI blood test analyser is powered by a proprietary neural network comprising 2.78 trillion parameters. According to internal validation studies, the platform achieves accuracy rates between 98.7% and 99.84% when interpreting standard blood panel results. By converting complex laboratory values into clear, patient-friendly health reports, Kantesti bridges a critical gap between raw diagnostic data and meaningful health insights.

The platform delivers personalised outputs that include biomarker explanations, nutritional guidance, and supplement recommendations tailored to individual health profiles. This approach enables users to better understand their results while identifying areas that may require professional medical follow-up.

A member of Kantesti’s medical advisory board noted that traditional blood reports often leave patients uncertain about next steps. By applying advanced neural architectures, the platform provides interpretive depth typically associated with consultations across multiple medical specialities, improving patient understanding without replacing clinical judgement.

Addressing a Global Healthcare Bottleneck

Globally, healthcare systems face mounting pressure to deliver timely diagnostics amid growing patient volumes. The World Health Organization has highlighted that delayed or insufficient interpretation of routine laboratory tests contributes significantly to preventable complications.

Kantesti addresses this challenge through instant AI-driven blood test interpretation. Users upload laboratory reports via the platform’s web or mobile interface and receive comprehensive assessments within minutes. Reports include contextualised reference ranges, identification of potential health concerns, personalised nutrition plans, evidence-based supplement suggestions, and trend analysis for users tracking results over time.

Strategic Expansion Across Europe

The company’s expansion into Germany, Italy, and France reflects rising European demand for AI-assisted healthcare solutions. Germany’s advanced digital health infrastructure, Italy’s strong private healthcare ecosystem, and France’s progressive stance on health technology adoption have made these markets strategic priorities.

Julian Emirhan Bulut, Founder and CEO of PIYA AI, said Europe represents a mature and discerning market for AI-driven diagnostic support. He emphasised that Kantesti’s presence in Cologne, Milan, and Paris strengthens its ability to serve European users while maintaining strict compliance with EU data protection and privacy regulations.

Secure Infrastructure and Industry Partnerships

Kantesti operates on enterprise-grade cloud infrastructure, with regionally optimised data centres to ensure GDPR compliance. The platform has established technology partnerships with Microsoft, NVIDIA, Google Cloud, and Cloudflare, ensuring scalability, reliability, and high-level data security.

Its proprietary neural network has been trained on large volumes of anonymised clinical datasets and continues to evolve through integration of emerging medical research and biomarker science.

Recognition and Future Roadmap

Kantesti has received industry recognition through programmes such as the Microsoft for Startups Founders Hub and the NVIDIA Inception Program, granting access to advanced AI infrastructure and technical expertise.

Looking ahead, the platform plans to expand its analytical capabilities with additional biomarker categories, enhanced predictive health modelling, and deeper personalisation incorporating genetic and lifestyle factors. Growth in mobile app adoption further reflects demand for accessible, continuous health monitoring tools.

As healthcare systems worldwide seek scalable solutions for preventive care and early insight, Kantesti’s AI blood test analysis platform is increasingly positioned as a key enabler of patient empowerment and data-driven health management.

If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.